GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (LTS:0SGC) » Definitions » Cyclically Adjusted Book per Share

Arbutus Biopharma (LTS:0SGC) Cyclically Adjusted Book per Share : $3.47 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Arbutus Biopharma's adjusted book value per share for the three months ended in Mar. 2024 was $0.636. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.47 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Arbutus Biopharma's average Cyclically Adjusted Book Growth Rate was -5.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 2.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Arbutus Biopharma was 10.00% per year. The lowest was -6.90% per year. And the median was 0.60% per year.

As of today (2024-06-21), Arbutus Biopharma's current stock price is $2.988. Arbutus Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.47. Arbutus Biopharma's Cyclically Adjusted PB Ratio of today is 0.86.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arbutus Biopharma was 8.34. The lowest was 0.24. And the median was 0.91.


Arbutus Biopharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted Book per Share Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.55 4.17 3.52

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 3.53 3.57 3.52 3.47

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PB Ratio falls into.



Arbutus Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arbutus Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.636/131.7762*131.7762
=0.636

Current CPI (Mar. 2024) = 131.7762.

Arbutus Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.762 100.560 6.240
201409 4.286 100.428 5.624
201412 3.923 99.070 5.218
201503 10.975 99.621 14.517
201506 10.837 100.684 14.184
201509 10.149 100.392 13.322
201512 10.036 99.792 13.253
201603 9.850 100.470 12.919
201606 7.871 101.688 10.200
201609 7.597 101.861 9.828
201612 3.702 101.863 4.789
201703 3.437 102.862 4.403
201706 3.195 103.349 4.074
201709 3.041 104.136 3.848
201712 2.410 104.011 3.053
201803 2.070 105.290 2.591
201806 2.056 106.317 2.548
201809 1.655 106.507 2.048
201812 1.307 105.998 1.625
201903 0.912 107.251 1.121
201906 0.566 108.070 0.690
201909 -0.893 108.329 -1.086
201912 -0.996 108.420 -1.211
202003 -0.956 108.902 -1.157
202006 -1.074 108.767 -1.301
202009 -0.571 109.815 -0.685
202012 -0.522 109.897 -0.626
202103 -0.395 111.754 -0.466
202106 -0.557 114.631 -0.640
202109 -0.277 115.734 -0.315
202112 1.169 117.630 1.310
202203 1.115 121.301 1.211
202206 1.029 125.017 1.085
202209 0.953 125.227 1.003
202212 0.869 125.222 0.914
202303 0.872 127.348 0.902
202306 0.807 128.729 0.826
202309 0.712 129.860 0.723
202312 0.624 129.419 0.635
202403 0.636 131.776 0.636

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Arbutus Biopharma  (LTS:0SGC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arbutus Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.988/3.47
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arbutus Biopharma was 8.34. The lowest was 0.24. And the median was 0.91.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Arbutus Biopharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (LTS:0SGC) Business Description

Industry
Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (LTS:0SGC) Headlines

No Headlines